Valve Thrombosis in TTVR Not Uncommon: Meta-analysis
Tausif Salim, Principal Clinical Scientist at Abbott, posted on LinkedIn:
”I’ve been closely and enthusiastically following the topic of valve thrombosis – both clinical and subclinical – following transcatheter tricuspid valve replacement (TTVR). A recent meta-analysis article really highlights some critical considerations that device designers should take into account:
– The tricuspid valve functions under low pressure and is located on the right side of the heart, where blood flow tends to be more stagnant compared to the left side. This reduced blood washout increases the risk of valve thrombosis.
– Some degree of valve thrombosis after TTVR seems inevitable. The key questions are: how significant is the issue, and what are the most effective strategies for managing it?
While thrombosis in the tricuspid position isn’t unexpected, there’s a clear opportunity to reduce its incidence through improved device design from the outset.
Moreover, we must consider the differences in clot formation kinetics and clot material properties between right and left sides of the heart. Hypoxia, which is known to promote thrombosis, adds another point for consideration.
From a scientific standpoint, this is particularly fascinating. Virchow’s triad – developed by Dr. Rudolph Virchow in 1856 to explain venous thrombosis and pulmonary embolism – identified three primary contributors to thrombus formation: venous stasis, endothelial injury, and blood hypercoagulability. The current findings in TTVR thrombosis seem to bring his foundational theory full circle.”
Read the full article here.
Title: Valve Thrombosis in TTVR Not Uncommon: Meta-analysis
Author: Caitlin E. Cox
Stay updated with Hemostasis Today.
-
Oct 21, 2025, 06:59Samwel Mikaye: Polycythemia and the Risk of Blood Clots
-
Oct 21, 2025, 06:58Samuel Nweke: Interpreting D-Dimer Results
-
Oct 21, 2025, 05:20Ewa Fiorentino Rozek: APS - When “Unprovoked” Clots And Pregnancy Loss Connect
-
Oct 21, 2025, 03:503 Questions With Abigail Ajanel Gomez – Touch Haematology Future Leader 2025
-
Oct 21, 2025, 01:57Mohamed Reda: Clotting Factors — The Key Players in Blood Coagulation
-
Oct 22, 2025, 10:35Evaluating a Novel Human Fibrinogen Concentrate (BT524) for Congenital Fibrinogen Deficiency
-
Oct 22, 2025, 09:37Jurjen Krommenhoek and Colleagues Propose a Clinical Care Pathway for Major Bleeding Survivors
-
Oct 22, 2025, 09:32Ishac Nazy: Proud Moment For Our Team!
-
Oct 22, 2025, 09:16Richard Benjamin Shares Results of The ReCePI Phase III Clinical Study
-
Oct 21, 2025, 11:13Hanny Al Samkari's Commentary on Iron Deficiency Anemia in Inherited Bleeding Disorders
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 21, 2025, 06:58Arno Nierich: How Caffeine Affects Red Blood Cells and Blood Storage
-
Oct 21, 2025, 06:43Could Gene Therapy Offer Lasting Quality of Life for People with Hemophilia B?
-
Oct 21, 2025, 06:18Katerina Akassoglou Receives Zenith Fellows Award to Advance Alzheimer’s Research
-
Oct 16, 2025, 06:07ClearPlasma - A New Breakthrough in Stopping Life-Threatening Bleeds
-
Oct 22, 2025, 10:46Conversation with Ferran Nadeu – Touch Haematology Future Leader 2025
-
Oct 22, 2025, 10:32Lynn Malec - The New Director of the CCBD and Pharmacy at Children's Wisconsin
-
Oct 22, 2025, 09:41Deanna Joseph: Feeling Inspired and Deeply Grateful After Attending the 2025 HTRS SEARCH Workshop
-
Oct 22, 2025, 08:41Maryum Salim Reflects on Her Experience at the HTRS SEARCH Workshop
-
Oct 22, 2025, 08:36Emilya Huseynova to Speak at AABB 2025